FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs

Blood

Volumn 121, Issue 19, 2013, Pages 3867-3878

  Bueno, Clara ^a   Ayllón, Verónica ^a   Montes, Rosa ^a   Navarro Montero, Oscar ^a   Ramos Mejia, Verónica ^a   Real, Pedro J ^a   Romero Moya, Damià ^a   Araúzo Bravo, Marcos J ^b   Menendez, Pablo ^a,c,d  

^a UNIVERSITY OF GRANADA   (Spain)

^b MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AF4 PROTEIN; CD135 ANTIGEN; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE LEUKEMIA PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN; PROTEIN KINASE B; REX1 PROTEIN; STAGE SPECIFIC EMBRYO ANTIGEN 3; STAGE SPECIFIC EMBRYO ANTIGEN 4; STAT5 PROTEIN; TRA 1 60 PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; FLT3 PROTEIN, HUMAN; MLL AF4 FUSION PROTEIN, HUMAN; MLL-AF4 FUSION PROTEIN, HUMAN; ONCOPROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL FATE; CELL MIGRATION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CFU COUNTING; CHEMOTAXIS; CONTROLLED STUDY; DEVELOPMENT; DNA DAMAGE RESPONSE; ECTOPIC EXPRESSION; EMBRYO; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HEMATOPOIESIS; HEMATOPOIETIC CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN EMBRYONIC STEM CELL; IN VITRO STUDY; LEUKEMOGENESIS; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE EXPRESSION; ANIMAL; CELL CULTURE; CELL LINEAGE; EMBRYONIC STEM CELL; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; EMBRYONIC STEM CELLS; ENZYME ACTIVATION; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION PROFILING; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, SCID; MICROARRAY ANALYSIS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION;

MLCS; MLOWN;

EID: 84880468268     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-470146     Document Type: Article

References (50)

1. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol. 2004;51(1):1-28.
2. Bueno C, Montes R, Catalina P, Rodríguez R, Menendez P. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. Leukemia. 2011;25(3):400-410.
3. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3(9):639-649.
4. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11): 823-833.
5. Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature. 1993;363(6427): 358-360.
6. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood. 2003;102(7):2321-2333.
7. Bursen A, Schwabe K, Rüster B, Henschler R, Ruthardt M, Dingermann T, et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood. 2010; 115(17):3570-3579.
8. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine MLL-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood. 2006;108(2): 669-677.
9. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(5): 355-368.
10. Metzler M, Forster A, Pannell R, et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene. 2006;25(22):3093-3103.
11. Lensch MW, Daley GQ. Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells. Blood. 2006;107(7): 2605-2612.
12. Menendez P, Bueno C, Wang L. Human embryonic stem cells: A journey beyond cell replacement therapies. Cytotherapy. 2006;8(6): 530-541.
13. Montes R, Ayllón V, Gutierrez-Aranda I, et al. Enforced expression of MLL-AF4 fusion in cord blood CD341 cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood. 2011;117(18):4746-4758.
14. Bueno C, Montes R, Melen GJ, et al. A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification. Cell Res. 2012;22(6): 986-1002.
15. Armstrong SA, Mabon ME, Silverman LB, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103(9):3544-3546.
16. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103(3):1085-1088.
17. Chillón MC, Gómez-Casares MT, López-Jorge CE, et al. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF41 and MLL-germline acute lymphoblastic leukemia. Leukemia. 2012;26(11):2360-2366.
18. Yamaguchi H, Hanawa H, Uchida N, et al. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/FLT3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression. Exp Hematol. 2009;37(6): 701-714.
19. Guenther MG, Lawton LN, Rozovskaia T, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008;22(24):3403-3408.
20. Stam RW, den Boer ML, Schneider P, Meier M, Beverloo HB, Pieters R. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia. Haematologica. 2007;92(11):1565-1568.
21. Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 2007;110(7):2774-2775.
22. Real PJ, Ligero G, Ayllon V, et al. SCL/TAL1 regulates hematopoietic specification from human embryonic stem cells. Mol Ther. 2012;20(7): 1443-1453.
23. Bueno C, Catalina P, Melen GJ, et al. Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis. 2009;30(9): 1628-1637.
24. Cortes JL, Sanchez L, Ligero G, et al. Mesenchymal stem cells facilitate the derivation of human embryonic stem cells from cryopreserved poor-quality embryos. Hum Reprod. 2009;24(8): 1844-1851.
25. Ramos-Mejia V, Melen GJ, Sanchez L, et al. Nodal/Activin signaling predicts human pluripotent stem cell lines prone to differentiate toward the hematopoietic lineage. Mol Ther. 2010;18(12): 2173-2181.
26. Ramos-Mejía V, Bueno C, Roldan M, et al. The adaptation of human embryonic stem cells to different feeder-free culture conditions is accompanied by a mitochondrial response. Stem Cells Dev. 2012;21(7):1145-1155.
27. Ramos-Mejía V, Fernández AF, Ayllón V, et al. Maintenance of human embryonic stem cells in mesenchymal stem cell-conditioned media augments hematopoietic specification. Stem Cells Dev. 2012;21(9):1549-1558.
28. Sánchez L, Gutierrez-Aranda I, Ligero G, et al. Maintenance of human embryonic stem cells in media conditioned by human mesenchymal stem cells obviates the requirement of exogenous basic fibroblast growth factor supplementation. Tissue Eng Part C Methods 2012.18(5):387-396.
29. Catalina P, Bueno C, Montes R, et al. Genetic stability of human embryonic stem cells: A first-step toward the development of potential hESC-based systems for modeling childhood leukemia. Leuk Res. 2009;33(7):980-990.
30. Montes R, Ligero G, Sanchez L, et al. Feeder-free maintenance of hESCs in mesenchymal stem cell-conditioned media: distinct requirements for TGF-beta and IGF-II. Cell Res. 2009;19(6): 698-709.
31. Ramos-Mejía V, Montes R, Bueno C, et al. Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD341 progenitors. PLoS ONE. 2012;7(4):e35824.
32. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells. 2010;28(9):1568-1570.
33. Barroso-delJesus A, Lucena-Aguilar G, Sanchez L, Ligero G, Gutierrez-Aranda I, Menendez P. The Nodal inhibitor Lefty is negatively modulated by the microRNA miR-302 in human embryonic stem cells. FASEB J. 2011;25(5):1497-1508.
34. Rodriguez R, Rubio R, Gutierrez-Aranda I, et al. FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. Stem Cells. 2011;29(2): 179-192.
35. Rubio R, Gutierrez-Aranda I, Sáez-Castillo AI, et al. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene. 2012 Dec 10. [Epub ahead of print]
36. Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene. 2010;29(37):5120-5134.
37. Wang L, Li L, Shojaei F, et al. Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity. 2004; 21(1):31-41.
38. Furuichi Y, Goi K, Inukai T, et al. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents. Cancer Res. 2007;67(20):9852-9861.
39. Emerenciano M, Menezes J, Vasquez ML, Zalcberg I, Thuler LC, Pombo-de-Oliveira MS; Brazilian Collaborative Study Group of Infant Acute Leukemia. Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia. Leuk Lymphoma. 2008;49(12): 2291-2297.
40. Bardini M, Galbiati M, Lettieri A, et al. Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia. 2011;25(1):175-178.
41. Bardini M, Spinelli R, Bungaro S, et al. DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia. 2010;24(1): 169-176.
42. Ono R, Nakajima H, Ozaki K, et al. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest. 2005;115(4): 919-929.
43. Takacova S, Slany R, Bartkova J, et al. DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo. Cancer Cell. 2012;21(4):517-531.
44. Greenblatt S, Small D. FLT3 in lineage specification and plasticity. Oncotarget. 2012; 3(5):576-580.
45. Armstrong L, Hughes O, Yung S, et al. The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet. 2006;15(11):1894-1913.
46. Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20): 4205-4214.
47. Stumpel DJ, Schneider P, Seslija L, et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia. 2012;26(4): 682-692.
48. Stumpel DJ, Schneider P, van Roon EH, et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood. 2009;114(27):5490-5498.
49. Stumpel DJ, Schneider P, van Roon EH, Pieters R, Stam RW. Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia. Eur J Cancer. 2013;49(1):175-184.
50. Benedikt A, Baltruschat S, Scholz B, et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia. 2011;25(1):135-144.